Stock Traders Purchase High Volume of Call Options on Adamas Pharmaceuticals (ADMS)
Adamas Pharmaceuticals Inc (NASDAQ:ADMS) was the target of unusually large options trading on Tuesday. Traders acquired 1,604 call options on the stock. This is an increase of approximately 1,504% compared to the average daily volume of 100 call options.
Adamas Pharmaceuticals (NASDAQ ADMS) opened at $35.61 on Friday. The company has a market cap of $811.16, a P/E ratio of -10.60 and a beta of 1.13. The company has a current ratio of 8.35, a quick ratio of 8.32 and a debt-to-equity ratio of 0.41. Adamas Pharmaceuticals has a fifty-two week low of $13.50 and a fifty-two week high of $38.22.
Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.03). The company’s revenue was down 99.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.66) EPS. research analysts predict that Adamas Pharmaceuticals will post -3.84 EPS for the current fiscal year.
Large investors have recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in Adamas Pharmaceuticals in the third quarter valued at $110,000. Quantbot Technologies LP acquired a new position in shares of Adamas Pharmaceuticals during the third quarter valued at about $119,000. Tower Research Capital LLC TRC acquired a new position in shares of Adamas Pharmaceuticals during the second quarter valued at about $109,000. Sei Investments Co. raised its holdings in shares of Adamas Pharmaceuticals by 1,105.0% during the third quarter. Sei Investments Co. now owns 8,760 shares of the specialty pharmaceutical company’s stock valued at $185,000 after purchasing an additional 8,033 shares during the period. Finally, Virtu KCG Holdings LLC acquired a new position in shares of Adamas Pharmaceuticals during the second quarter valued at about $184,000. Institutional investors own 79.40% of the company’s stock.
Several equities research analysts have recently weighed in on the company. Needham & Company LLC reiterated a “buy” rating and issued a $38.00 price objective on shares of Adamas Pharmaceuticals in a research note on Sunday, September 17th. Mizuho reissued a “buy” rating and issued a $48.00 target price (up from $26.00) on shares of Adamas Pharmaceuticals in a report on Tuesday, September 19th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $30.00 price objective on shares of Adamas Pharmaceuticals in a report on Wednesday, September 20th. Zacks Investment Research raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, September 21st. Finally, Noble Financial restated a “buy” rating and issued a $33.00 price objective on shares of Adamas Pharmaceuticals in a research report on Friday, September 29th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. Adamas Pharmaceuticals has an average rating of “Buy” and an average target price of $44.86.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.